Upgrades
- According to Roth Capital, the prior rating for Amplify Energy Corp AMPY was changed from Neutral to Buy. For the second quarter, Amplify Energy had an EPS of $0.73, compared to year-ago quarter EPS of $0.92. The current stock performance of Amplify Energy shows a 52-week-high of $9.86 and a 52-week-low of $3.10. Moreover, at the end of the last trading period, the closing price was at $9.39.
- According to Barclays, the prior rating for Intel Corp INTC was changed from Underweight to Equal-Weight. For the third quarter, Intel had an EPS of $0.59, compared to year-ago quarter EPS of $1.71. The stock has a 52-week-high of $56.28 and a 52-week-low of $24.59. At the end of the last trading period, Intel closed at $26.27.
- Wolfe Research upgraded the previous rating for First Solar Inc FSLR from Peer Perform to Outperform. For the third quarter, First Solar had an EPS of $0.46, compared to year-ago quarter EPS of $0.42. The stock has a 52-week-high of $145.74 and a 52-week-low of $59.60. At the end of the last trading period, First Solar closed at $131.18.
- According to Piper Sandler, the prior rating for Gilead Sciences Inc GILD was changed from Neutral to Overweight. Gilead Sciences earned $1.90 in the third quarter, compared to $2.65 in the year-ago quarter. The stock has a 52-week-high of $73.39 and a 52-week-low of $57.16. At the end of the last trading period, Gilead Sciences closed at $70.20.
- For Unity Software Inc U, Piper Sandler upgraded the previous rating of Neutral to Overweight. In the second quarter, Unity Software showed an EPS of $0.18, compared to $0.02 from the year-ago quarter. At the moment, the stock has a 52-week-high of $144.69 and a 52-week-low of $26.92. Unity Software closed at $27.88 at the end of the last trading period.
- Keybanc upgraded the previous rating for MYR Group Inc MYRG from Sector Weight to Overweight. For the third quarter, MYR Group had an EPS of $1.09, compared to year-ago quarter EPS of $1.35. The current stock performance of MYR Group shows a 52-week-high of $112.11 and a 52-week-low of $74.77. Moreover, at the end of the last trading period, the closing price was at $80.28.
See all analyst ratings upgrades.
Downgrades
- For XPeng Inc XPEV, Citigroup downgraded the previous rating of Buy to Sell. For the second quarter, XPeng had an EPS of $0.43, compared to year-ago quarter EPS of $0.21. The current stock performance of XPeng shows a 52-week-high of $51.50 and a 52-week-low of $6.25. Moreover, at the end of the last trading period, the closing price was at $7.36.
- For Core Scientific Inc CORZ, B. Riley Securities downgraded the previous rating of Buy to Neutral. In the second quarter, Core Scientific showed an EPS of $0.18, compared to $0.13 from the year-ago quarter. At the moment, the stock has a 52-week-high of $11.49 and a 52-week-low of $0.20. Core Scientific closed at $0.22 at the end of the last trading period.
- According to Evercore ISI Group, the prior rating for Globe Life Inc GL was changed from Outperform to In-Line. Globe Life earned $2.15 in the third quarter, compared to $1.78 in the year-ago quarter. At the moment, the stock has a 52-week-high of $116.56 and a 52-week-low of $87.87. Globe Life closed at $111.91 at the end of the last trading period.
- According to Truist Securities, the prior rating for UserTesting Inc USER was changed from Buy to Hold. In the third quarter, UserTesting showed an EPS of $0.04, compared to $0.45 from the year-ago quarter. At the moment, the stock has a 52-week-high of $11.99 and a 52-week-low of $3.31. UserTesting closed at $7.40 at the end of the last trading period.
- Credit Suisse downgraded the previous rating for Travel+Leisure Co TNL from Outperform to Underperform. Travel+Leisure earned $1.28 in the third quarter, compared to $1.19 in the year-ago quarter. At the moment, the stock has a 52-week-high of $63.19 and a 52-week-low of $33.57. Travel+Leisure closed at $37.20 at the end of the last trading period.
- According to Oppenheimer, the prior rating for Edwards Lifesciences Corp EW was changed from Outperform to Perform. For the third quarter, Edwards Lifesciences had an EPS of $0.61, compared to year-ago quarter EPS of $0.54. The current stock performance of Edwards Lifesciences shows a 52-week-high of $131.10 and a 52-week-low of $80.69. Moreover, at the end of the last trading period, the closing price was at $86.30.
- According to UBS, the prior rating for The Western Union Co WU was changed from Neutral to Sell. For the second quarter, The Western Union had an EPS of $0.51, compared to year-ago quarter EPS of $0.48. At the moment, the stock has a 52-week-high of $20.40 and a 52-week-low of $13.05. The Western Union closed at $13.86 at the end of the last trading period.
- DA Davidson downgraded the previous rating for Paylocity Holding Corp PCTY from Buy to Neutral. For the fourth quarter, Paylocity Holding had an EPS of $0.80, compared to year-ago quarter EPS of $0.46. The stock has a 52-week-high of $276.88 and a 52-week-low of $152.01. At the end of the last trading period, Paylocity Holding closed at $226.84.
- According to William Blair, the prior rating for TriMas Corp TRS was changed from Outperform to Market Perform. In the third quarter, TriMas showed an EPS of $0.40, compared to $0.57 from the year-ago quarter. The current stock performance of TriMas shows a 52-week-high of $37.65 and a 52-week-low of $22.05. Moreover, at the end of the last trading period, the closing price was at $22.53.
- For West Pharmaceutical Services Inc WST, B of A Securities downgraded the previous rating of Buy to Neutral. For the third quarter, West Pharmaceutical Servs had an EPS of $2.03, compared to year-ago quarter EPS of $2.06. At the moment, the stock has a 52-week-high of $468.05 and a 52-week-low of $206.19. West Pharmaceutical Servs closed at $221.23 at the end of the last trading period.
- Exane BNP Paribas downgraded the previous rating for Axalta Coating Systems Ltd AXTA from Outperform to Neutral. In the third quarter, Axalta Coating Sys showed an EPS of $0.39, compared to $0.39 from the year-ago quarter. The current stock performance of Axalta Coating Sys shows a 52-week-high of $34.12 and a 52-week-low of $20.66. Moreover, at the end of the last trading period, the closing price was at $23.69.
- Edward Jones downgraded the previous rating for Meta Platforms Inc META from Buy to Hold. In the third quarter, Meta Platforms showed an EPS of $1.64, compared to $3.22 from the year-ago quarter. At the moment, the stock has a 52-week-high of $199.45 and a 52-week-low of $11.73. Meta Platforms closed at $97.94 at the end of the last trading period.
- According to Baird, the prior rating for Stanley Black & Decker Inc SWK was changed from Outperform to Neutral. Stanley Black & Decker earned $0.76 in the third quarter, compared to $2.77 in the year-ago quarter. At the moment, the stock has a 52-week-high of $196.52 and a 52-week-low of $70.24. Stanley Black & Decker closed at $75.67 at the end of the last trading period.
- For Dana Inc DAN, RBC Capital downgraded the previous rating of Outperform to Sector Perform. Dana earned $0.24 in the third quarter, compared to $0.41 in the year-ago quarter. At the moment, the stock has a 52-week-high of $25.51 and a 52-week-low of $11.17. Dana closed at $16.03 at the end of the last trading period.
- According to Deutsche Bank, the prior rating for Caterpillar Inc CAT was changed from Buy to Hold. Caterpillar earned $3.95 in the third quarter, compared to $2.66 in the year-ago quarter. The current stock performance of Caterpillar shows a 52-week-high of $237.90 and a 52-week-low of $160.60. Moreover, at the end of the last trading period, the closing price was at $212.14.
- For L3Harris Technologies Inc LHX, Raymond James downgraded the previous rating of Outperform to Market Perform. In the third quarter, L3Harris Technologies showed an EPS of $3.26, compared to $3.21 from the year-ago quarter. The current stock performance of L3Harris Technologies shows a 52-week-high of $279.71 and a 52-week-low of $206.04. Moreover, at the end of the last trading period, the closing price was at $252.80.
See all analyst ratings downgrades.
Initiations
- EF Hutton initiated coverage on Enovix Corp ENVX with a Buy rating. The price target for Enovix is set to $25.00. In the second quarter, Enovix showed an EPS of $0.13, compared to $0.21 from the year-ago quarter. The stock has a 52-week-high of $28.17 and a 52-week-low of $7.26. At the end of the last trading period, Enovix closed at $18.10.
- National Bank Of Canada initiated coverage on Alithya Group Inc ALYA with a Sector Perform rating. The price target for Alithya Group is set to $3.25. For the first quarter, Alithya Group had an EPS of $0.03, compared to year-ago quarter EPS of $0.02. The stock has a 52-week-high of $3.09 and a 52-week-low of $1.69. At the end of the last trading period, Alithya Group closed at $1.79.
- BTIG initiated coverage on MariMed Inc MRMD with a Buy rating. The price target for MariMed is set to $0.85. For the second quarter, MariMed had an EPS of $0.00, compared to year-ago quarter EPS of $0.02. The stock has a 52-week-high of $0.94 and a 52-week-low of $0.40. At the end of the last trading period, MariMed closed at $0.53.
- JP Morgan initiated coverage on Physicians Realty Trust DOC with a Neutral rating. The price target for Physicians Realty Trust is set to $17.00. Physicians Realty Trust earned $0.27 in the second quarter, compared to $0.26 in the year-ago quarter. At the moment, the stock has a 52-week-high of $19.12 and a 52-week-low of $13.42. Physicians Realty Trust closed at $14.77 at the end of the last trading period.
- With a Buy rating, B. Riley Securities initiated coverage on AST SpaceMobile Inc ASTS. The price target seems to have been set at $15.00 for AST SpaceMobile. For the second quarter, AST SpaceMobile had an EPS of $0.06, compared to year-ago quarter EPS of $0.39. At the moment, the stock has a 52-week-high of $14.27 and a 52-week-low of $4.84. AST SpaceMobile closed at $5.91 at the end of the last trading period.
- With a Neutral rating, B. Riley Securities initiated coverage on Mirati Therapeutics Inc MRTX. The price target seems to have been set at $72.00 for Mirati Therapeutics. For the second quarter, Mirati Therapeutics had an EPS of $3.18, compared to year-ago quarter EPS of $3.23. The stock has a 52-week-high of $151.15 and a 52-week-low of $32.96. At the end of the last trading period, Mirati Therapeutics closed at $66.38.
- BTIG initiated coverage on Ascend Wellness Holdings Inc AAWH with a Buy rating. The price target for Ascend Wellness Holdings is set to $4.00. The stock has a 52-week-high of $6.76 and a 52-week-low of $1.52. At the end of the last trading period, Ascend Wellness Holdings closed at $2.00.
- HC Wainwright & Co. initiated coverage on Eliem Therapeutics Inc ELYM with a Buy rating. The price target for Eliem Therapeutics is set to $6.00. Eliem Therapeutics earned $0.56 in the second quarter, compared to $3.11 in the year-ago quarter. The stock has a 52-week-high of $13.74 and a 52-week-low of $2.52. At the end of the last trading period, Eliem Therapeutics closed at $3.03.
- With a Buy rating, Goldman Sachs initiated coverage on CinCor Pharma Inc CINC. The price target seems to have been set at $67.00 for CinCor Pharma. For the second quarter, CinCor Pharma had an EPS of $0.56, compared to year-ago quarter EPS of $4.81. At the moment, the stock has a 52-week-high of $43.15 and a 52-week-low of $13.00. CinCor Pharma closed at $32.72 at the end of the last trading period.
- With an Outperform rating, Wedbush initiated coverage on Geron Corp GERN. The price target seems to have been set at $5.00 for Geron. Geron earned $0.07 in the second quarter, compared to $0.09 in the year-ago quarter. The current stock performance of Geron shows a 52-week-high of $3.06 and a 52-week-low of $0.99. Moreover, at the end of the last trading period, the closing price was at $2.30.
- Wedbush initiated coverage on Imago BioSciences Inc IMGO with an Outperform rating. The price target for Imago BioSciences is set to $25.00. Imago BioSciences earned $0.41 in the second quarter, compared to $8.13 in the year-ago quarter. At the moment, the stock has a 52-week-high of $27.04 and a 52-week-low of $11.56. Imago BioSciences closed at $16.53 at the end of the last trading period.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in